Will Erlotinib Prevent Disease Recurrence in Patients with Early Stage EGFR Positive Non-small Cell Lung Cancer?


Dr. Joel Neal of Stanford University Medical Center discusses the SELECT clinical trial which studied early stage non-small cell lung cancer patients and whether or not Tarceva (erlotinib) would prevent disease recurrence. February 2014.


Targeted Therapy as Adjuvant Treatment: Should We Extrapolate from Advanced NSCLC to Earlier Stage?


This past week, I saw a new patient who had just moved from another part of the country and needed long-term management of her high risk lung cancer.  A never-smoking Asian woman, she was found to have a stage IIIA lung cancer with "N2" mediastinal lymph nodes involving cancer in her mid-chest.